Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Clinical trial NCT06533761 · RECRUITING
Trial details
- NCT number
- NCT06533761
- Sponsor
- Stelexis BioSciences
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-28
- Primary completion
- 2027-07-15
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.